Full text is available at the source.
Abstract
A serum-stable bivalent prostate-specific membrane antigen aptamer-AR-V7 siRNA chimera (PAP) can effectively knock down both full-length androgen receptors and AR-V7 in prostate cancer cells.
- AR-V7 is associated with resistance to FDA-approved second-generation androgen receptor antagonists enzalutamide and abiraterone.
- Current androgen receptor antagonists cannot target AR-V7 due to its structural characteristics.
- Targeting the androgen receptor N-terminal domain is crucial to overcoming enzalutamide resistance.
- PAP has been shown to resensitize prostate cancer cell lines to enzalutamide treatment.
- In mouse models, the combination of enzalutamide and PAP significantly inhibits the growth of prostate cancer xenografts.
- PAP demonstrates low toxicity, suggesting its potential as a new antiandrogen treatment for enzalutamide-resistant prostate cancer.
Simplified